ODYSSEY OUTCOMES: Addition of PCSK9i to Background Statin Therapy Further Reduces MACE



*1-12 months from index ACS event

**Blinded adjustment of alirocumab dose to target achieved LDL-C 25- 50 mg/dl and avoid sustained levels <15 mg/dl

[a] Primary efficacy endpoint (a composite of death from CHD, nonfatal MI, fatal or nonfatal ischaemic stroke, or unstable angina requiring hospitalization)

HDL-C, High-density lipoprotein cholesterol; Q2W, every 2 weeks; SC, subcutaneous

ODYSSEY OUTCOMES: Addition of PCSK9i to Background Statin Therapy Further Reduces MACE



Safety: Incidence or adverse events and laboratory abnormalities was similar in the alirocumab group and the placebo group, apart from local injection-site reaction (3.8% in alirocumab group vs 2.1% in the placebo group, p<0.001)

[a] Primary efficacy endpoint (a composite of death from CHD, nonfatal MI, fatal or nonfatal ischaemic stroke, or unstable angina requiring hospitalization)

CHD, Coronary Heart Disease; CI, Confidence Interval; MI, Myocardial Infarction

---

All-Cause Death[2]



*Nominal p-value
†Based on cumulative incidence

Alirocumab: Clinical Safety Profile

- Overall, in ODYSSEY OUTCOMES, no statistically significant differences were observed in incidence of adverse events or laboratory abnormalities between alirocumab and placebo, except for local injection-site reactions, which occurred more often in the alirocumab group.[1]

  - No major differences in adverse events were observed between the vascular groups in the polyvascular disease analysis.[3]
  - Although adverse events were more frequent in older patients, there is no indication of a safety concern (over the duration of the trial) in either group.[4]

Table 3. Adverse Events and Laboratory Abnormalities.

Variable	Alirocumab (N=9451)	Placebo (N=9443)
Adverse events — no. (%)		
Any adverse event	7165 (75.8)	7282 (77.1)
Serious adverse event	2202 (23.3)	2350 (24.9)
Adverse event that led to death	181 (1.9)	222 (2.4)
Adverse event that led to discontinuation of the trial regimen	343 (3.6)	324 (3.4)
Local injection-site reaction	360 (3.8)	203 (2.1)
General allergic reaction	748 (7.9)	736 (7.8)
Diabetes worsening or diabetic complication among patients with diabetes at baseline — no./total no. (%)	506/2688 (18.8)	583/2747 (21.2)
New-onset diabetes among patients without diabetes at baseline — no./total no. (%)*	648/6763 (9.6)	676/6696 (10.1)
Neurocognitive disorder	143 (1.5)	167 (1.8)
Hepatic disorder	500 (5.3)	534 (5.7)
Cataracts	120 (1.3)	134 (1.4)
Hemorrhagic stroke, adjudicated	9 (<0.1)	16 (0.2)
Laboratory abnormalities at any time — no./total no. (%)		
Alanine aminotransferase >3 times upper limit of normal range	212/9369 (2.3)	228/9341 (2.4)
Aspartate aminotransferase >3 times upper limit of normal range	160/9367 (1.7)	166/9338 (1.8)
Total bilirubin >2 times upper limit of normal range	61/9368 (0.7)	78/9341 (0.8)
Creatine kinase >10 times upper limit of normal range	46/9369 (0.5)	48/9338 (0.5)
Antidrug antibodies†	67/9091 (0.7)	32/9097 (0.4)
Neutralizing antidrug antibodies	43/9091 (0.5)	6/9097 (<0.1)